Research programme: dendritic cell vaccines - DCPrime

Drug Profile

Research programme: dendritic cell vaccines - DCPrime

Alternative Names: DCP-002; DCP-00X

Latest Information Update: 16 Feb 2016

Price : $50

At a glance

  • Originator DCPrime
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 16 Feb 2016 Preclinical development is ongoing in the Netherlands
  • 21 Jun 2011 Preclinical trials in Solid tumours in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top